Pomegranate & Microbiota - The Health Benefits of Punicalagins

Punicalagins are bioactive compounds found in pomegranate (Punica granatum) as well as in various medicinal plants, in particular in species of the genus Terminalia. These very specific molecules belong to the ellagitannin family, a class of hydrolyzable tannins with proven health benefits.

Punicalagins are no exception: they have been identified as potentially beneficial in a myriad of health areas ranging from the cardiovascular [1-6] to the neurological spheres [7-13], but also for osteoarticular health [14-22].  They could even be of interest for therapeutic applications in the field of oncology [23-32].


Given that punicalagins are macromolecules whose systemic bioavailability after ingestion is far from optimal, one may wonder how this type of phytoactive is able to act beyond the digestive sphere.

In fact, these pleiotropic effects can be explained by two crucial aspects in the physiological action of punicalagins. In this article, these two aspects will be discussed in order to highlight the interest of pomegranate extracts rich in punicalagins and – by extension – other medicinal plants rich in ellagitannins such as the exotic Haritaki (Terminalia chebula – emblematic plant of Ayurveda), or our local Purple loosestrife (Lythrum salicaria).


As previously discussed, punicalagins have been identified as active and potentially beneficial for many areas of health, all of which correspond to applications where the health potential of the intestinal microbiota has been highlighted. Enough reason to investigate the impact of punicalagins on the microbiotic ecosystem.

As hydrolyzable tannins, punicalagins are water-soluble macromolecules with an affinity for the digestive mucosa and more specifically with the proteins that make up the mucus. They are therefore able to spread more efficiently on the mucous membrane, which makes punicalagins a significant asset for a targeted action on the intestinal mucosa. Once fixed, they will act on the oxidative and inflammatory status of the mucosa (therefore promoting the balance between microbiota and organism). On-site punicalagins will also limit the progression and virulence of certain pathogenic elements – whether fungal [33-34], bacterial [35-39] or viral [40-41] – while supporting the growth of symbiotic bacteria such as Bifidobacterium [42-43].

1.1. Punicalagins & Intestinal Epithelium

The positive effects of punicalagins on the microbiotic environment may also be indirect. For example, they have repeatedly been shown to exert significant influence on autophagic mechanisms [44-47]. Such activity is characteristic of phytonutrients that promote a healthy intestinal epithelium and ultimately microbiotic balance [48-49]. Indeed, protecting the integrity of the intestinal barrier is crucial to limiting excessive inflammatory response, which can carry harmful consequences for both the microbiota and the body.

1.2. Punicalagins & Liver Function

Another interesting finding is the positive effect of punicalagins on liver health [50-52], particularly via the Nrf2 pathway [53-55]. By supporting the optimal activity of the liver, punicalagins may promote a balanced production of bile acids. It is well known that the balance between bile and microbiota is a key factor of many microbiotic benefits [56].


A large portion of the world’s population has an intestinal microbiota that can metabolize punicalagins. This phenomenon leads to the release of ellagic acid, a molecule that can influence intestinal inflammation [57-59] but also shown to act at various other levels. In a third step, ellagic acid is finally converted into Urolithins, in particular into Urolithin A, a highly bioavailable molecule with direct action on the protection of the intestinal barrier [60-63], as well as numerous beneficial health properties.

This metabolic pathway characteristic of punicalagins allows them to act progressively and in the longer term, as they are metabolized from precursors to other active derivates. However, it should be noted that the maximization of this activity requires an efficient microbiota that is able to perform this conversion. This factor can lead to varying efficiency across individuals and has therefore led to the theory of metabotypes. Based on these elements, it appears that combining punicalagins with other molecules with known action on the microbiotic balance could be a good strategy to optimize the results.


Molecules with pleiotropic action such as punicalagins allow a large number of opportunities for synergistic combinations. However, it appears that an association with active ingredients capable of positively influencing the microbiotic environment could be of particular interest to ensure optimal efficiency.

Fast-acting molecules such as hydroxytyrosol from the olive tree (Olea europeae), chlorogenic acid found in green coffee (Coffea canephora), blueberry leaves (Vaccinium myrtillus) or even artichoke (Cynara scolymus), could allow a two-step action with a rapid effect of precursor phytoactives (hydroxytyrosol or chlorogenic acid), followed by a longer term effect of punicalagins for an efficient regulation of the microbiotic balance.

Another approach could be to combine a pomegranate extract rich in punicalagins with a fermented pomegranate extract, richer in its bioactive derivates Urolithin A and Ellagic Acid. This would allow patients to benefit from the advantages of ellagitannins and its metabolites, regardless of their microbiotic profile.

Finally, diversifying the supplemented tannins could also maximize the results: we could therefore consider combining pomegranate punicalagins with chebulagic acids of Haritaki (Terminalia chebula) or with those of Purple Loosestrife (Lythrum salicaria).


Punicalagins, like most active ingredients that promote microbiotic balance, have a variety of pleiotropic benefits on Health. They are also a good example that some molecules can have many health benefits through the microbiota despite not having significant systemic bioavailability.

A growing body of scientific evidence now points to the crucial impact of phytonutrients on the microbiotic environment, and it is suggested that the relationship between phytotherapy and the gut microbiota is anything but incidental. It could even appear as if the microbiome could be the “missing link” that would explain a large part of the benefits of medicinal plants on human health and lesser side effects.



[1] Anwaier G, Lian G, Ma GZ, Shen WL, Lee CI, Lee PL, Chang ZY, Wang YX, Tian XY, Gao XL, Chiu JJ, Qi R (2021) – “Punicalagin Attenuates Disturbed Flow-Induced Vascular Dysfunction by Inhibiting Force-Specific Activation of Smad1/5.” Front Cell Dev Biol. 2021 Jun 28;9:697539. doi: 10.3389/fcell.2021.697539. eCollection 2021.

[2] Fu F, Liu C, Shi R, Li M, Zhang M, Du Y, Wang Q, Li J, Wang G, Pei J, Ding M. (2021) – “Punicalagin Protects Against Diabetic Cardiomyopathy by Promoting Opa1-Mediated Mitochondrial Fusion via Regulating PTP1B-Stat3 Pathway.” Antioxid Redox Signal. 2021 Sep;35(8):618-641. doi: 10.1089/ars.2020.8248. Epub 2021 Jun 10.

[3] Yu LM, Dong X, Xue XD, Zhang J, Li Z, Wu HJ, Yang ZL, Yang Y, Wang HS (2019) – “Protection of the myocardium against ischemia/reperfusion injury by punicalagin through an SIRT1-NRF-2-HO-1-dependent mechanism.” Chem Biol Interact. 2019 Jun 1;306:152-162. doi: 10.1016/j.cbi.2019.05.003. Epub 2019 May 4.

[4] Ye M, Zhang L, Yan Y, Lin H (2019) – “Punicalagin protects H9c2 cardiomyocytes from doxorubicin-induced toxicity through activation of Nrf2/HO-1 signaling.” Biosci Rep. 2019 May 14;39(5):BSR20190229. doi: 10.1042/BSR20190229. Print 2019 May 31.

[5] Liu X, Cao K, Lv W, Feng Z, Liu J, Gao J, Li H, Zang W, Liu J (2019) – “Punicalagin attenuates endothelial dysfunction by activating FoxO1, a pivotal regulating switch of mitochondrial biogenesis.” Free Radic Biol Med. 2019 May 1;135:251-260. doi: 10.1016/j.freeradbiomed.2019.03.011. Epub 2019 Mar 13.

[6] Cao K, Xu J, Pu W, Dong Z, Sun L, Zang W, Gao F, Zhang Y, Feng Z, Liu J. (2015) – “Punicalagin, an active component in pomegranate, ameliorates cardiac mitochondrial impairment in obese rats via AMPK activation.” Sci Rep. 2015 Sep 15;5:14014. doi: 10.1038/srep14014.

[7] Jain V, Pareek A, Bhardwaj YR, Sinha SK, Gupta MM, Singh N (2021) – “Punicalagin and ellagic acid containing Punica granatum L. fruit rind extract prevents vincristine-induced neuropathic pain in rats: an in silico and in vivo evidence of GABAergic action and cytokine inhibition.” Nutr Neurosci. 2021 Aug 9:1-18. doi: 10.1080/1028415X.2021.1954293. Online ahead of print.

[8] Nasehi M, Mohammadi-Mahdiabadi-Hasani MH, Zarrindast MR, Zarrabian S (2021) – “Punicalagin effect on total sleep deprivation memory deficit in male Wistar rats.” J Integr Neurosci. 2021 Mar 30;20(1):87-93. doi: 10.31083/j.jin.2021.01.378.

[9] El-Missiry MA, ElKomy MA, Othman AI, AbouEl-Ezz AM (2018) – “Punicalagin ameliorates the elevation of plasma homocysteine, amyloid-beta, TNF-alpha and apoptosis by advocating antioxidants and modulating apoptotic mediator proteins in brain.” Biomed Pharmacother. 2018 Jun;102:472-480. doi: 10.1016/j.biopha.2018.03.096. Epub 2018 Apr 5.

[10] Clementi ME, Pani G, Sampaolese B, Tringali G (2018) – “Punicalagin reduces H(2)O(2)-induced cytotoxicity and apoptosis in PC12 cells by modulating the levels of reactive oxygen species.” Nutr Neurosci. 2018 Jul;21(6):447-454. doi: 10.1080/1028415X.2017.1306935. Epub 2017 Apr 9.

[11] Kim YE, Hwang CJ, Lee HP, Kim CS, Son DJ, Ham YW, Hellström M, Han SB, Kim HS, Park EK, Hong JT (2017) – “Inhibitory effect of punicalagin on lipopolysaccharide-induced neuroinflammation, oxidative stress and memory impairment via inhibition of nuclear factor-kappaB.” Neuropharmacology. 2017 May 1;117:21-32. doi: 10.1016/j.neuropharm.2017.01.025. Epub 2017 Jan 26.

[12] Yaidikar L, Thakur S (2015) – “Punicalagin attenuated cerebral ischemia-reperfusion insult via inhibition of proinflammatory cytokines, up-regulation of Bcl-2, down-regulation of Bax, and caspase-3.” Mol Cell Biochem. 2015 Apr;402(1-2):141-8. doi: 10.1007/s11010-014-2321-y. Epub 2015 Jan 3.

[13] Olajide OA, Kumar A, Velagapudi R, Okorji UP, Fiebich BL (2014) “Punicalagin inhibits neuroinflammation in LPS-activated rat primary microglia.” Mol Nutr Food Res. 2014 Sep;58(9):1843-51. doi: 10.1002/mnfr.201400163. Epub 2014 Jul 28.

[14] Liu F, Yang H, Li D, Wu X, Han Q. (2021) – “Punicalagin attenuates osteoarthritis progression via regulating Foxo1/Prg4/HIF3alpha axis.” Bone. 2021 Nov;152:116070. doi: 10.1016/j.bone.2021.116070. Epub 2021 Jun 23.

[15] Huang M, Wu K, Zeng S, Liu W, Cui T, Chen Z, Lin L, Chen D, Ouyang H (2021) – “Punicalagin Inhibited Inflammation and Migration of Fibroblast-Like Synoviocytes Through NF-kappaB Pathway in the Experimental Study of Rheumatoid Arthritis.” J Inflamm Res. 2021 May 12;14:1901-1913. doi: 10.2147/JIR.S302929. eCollection 2021.

[16] Kong J, Wang J, Gong X, Zheng X, Chen T (2020) – “Punicalagin Inhibits Tert-Butyl Hydroperoxide-Induced Apoptosis and Extracellular Matrix Degradation in Chondrocytes by Activating Autophagy and Ameliorates Murine Osteoarthritis.” Drug Des Devel Ther. 2020 Dec 15;14:5521-5533. doi: 10.2147/DDDT.S282932. eCollection 2020.

[17] Almowallad S, Huwait E, Al-Massabi R, Saddeek S, Gauthaman K, Prola A (2020) – “Punicalagin Regulates Key Processes Associated with Atherosclerosis in THP-1 Cellular Model.” Pharmaceuticals (Basel). 2020 Nov 8;13(11):372. doi: 10.3390/ph13110372.

[18] Feng X, Yang Q, Wang C, Tong W, Xu W. (2020) – “Punicalagin Exerts Protective Effects against Ankylosing Spondylitis by Regulating NF-kappaB-TH17/JAK2/STAT3 Signaling and Oxidative Stress.” Biomed Res Int. 2020 Sep 23;2020:4918239. doi: 10.1155/2020/4918239. eCollection 2020.

[19] Wang Q , Ge G , Liang X , Bai J , Wang W , Zhang W , Zheng K , Yang S , Wei M , Yang H , Xu Y , Liu B , Geng D (2020) – “Punicalagin ameliorates wear-particle-induced inflammatory bone destruction by bi-directional regulation of osteoblastic formation and osteoclastic resorption.” Biomater Sci. 2020 Sep 21;8(18):5157-5171. doi: 10.1039/d0bm00718h. Epub 2020 Aug 25.

[20] Wang W, Bai J, Zhang W, Ge G, Wang Q, Liang X, Li N, Gu Y, Li M, Xu W, Yang H, Xu Y, Geng D, Zhou J (2020) – “Protective Effects of Punicalagin on Osteoporosis by Inhibiting Osteoclastogenesis and Inflammation via the NF-kappaB and MAPK Pathways.” Front Pharmacol. 2020 May 15;11:696. doi: 10.3389/fphar.2020.00696. eCollection 2020.

[21] Iwatake M, Okamoto K, Tanaka T, Tsukuba T (2015) – “Punicalagin attenuates osteoclast differentiation by impairing NFATc1 expression and blocking Akt- and JNK-dependent pathways.” Mol Cell Biochem. 2015 Sep;407(1-2):161-72. doi: 10.1007/s11010-015-2466-3. Epub 2015 Jun 6.

[22] Iwatake M, Okamoto K, Tanaka T, Tsukuba T (2015) – “Punicalagin attenuates osteoclast differentiation by impairing NFATc1 expression and blocking Akt- and JNK-dependent pathways.” Mol Cell Biochem. 2015 Sep;407(1-2):161-72. doi: 10.1007/s11010-015-2466-3. Epub 2015 Jun 6.

[23] Berdowska I, Matusiewicz M, Fecka I. (2021) – “Punicalagin in Cancer Prevention-Via Signaling Pathways Targeting.” Nutrients. 2021 Aug 9;13(8):2733. doi: 10.3390/nu13082733.

[24] Fang L, Wang H, Zhang J, Fang X. (2021) – “Punicalagin induces ROS-mediated apoptotic cell death through inhibiting STAT3 translocation in lung cancer A549 cells.” J Biochem Mol Toxicol. 2021 Jun;35(6):1-10. doi: 10.1002/jbt.22771. Epub 2021 Mar 15.

[25] Wang XZ, Zhang SF, Yang ZH, Ye ZW, Liu J (2020) – “Punicalagin suppresses osteosarcoma growth and metastasis by regulating NF-kappaB signaling.” J Biol Regul Homeost Agents. 2020 Sep-Oct;34(5):1699-1708. doi: 10.23812/20-23-A.

[26] Ganesan T, Sinniah A, Chik Z, Alshawsh MA. (2020) – “Punicalagin Regulates Apoptosis-Autophagy Switch via Modulation of Annexin A1 in Colorectal Cancer.” Nutrients. 2020 Aug 13;12(8):2430. doi: 10.3390/nu12082430.

[27] Zhang L, Chinnathambi A, Alharbi SA, Veeraraghavan VP, Mohan SK, Zhang G (2020) – “Punicalagin promotes the apoptosis in human cervical cancer (ME-180) cells through mitochondrial pathway and by inhibiting the NF-kB signaling pathway.” Saudi J Biol Sci. 2020 Apr;27(4):1100-1106. doi: 10.1016/j.sjbs.2020.02.015. Epub 2020 Mar 4.

[28] Thotambailu AM, Bhandary BSK, Sharmila KP (2019) – “Protective Effect of Punica granatum Extract in Head and Neck Cancer Patients Undergoing Radiotherapy.” Indian J Otolaryngol Head Neck Surg. 2019 Oct;71(Suppl 1):318-320. doi: 10.1007/s12070-018-1297-4.

[29] Cheng X, Yao X, Xu S, Pan J, Yu H, Bao J, Guan H, Lu R, Zhang L (2018) – “Punicalagin induces senescent growth arrest in human papillary thyroid carcinoma BCPAP cells via NF-kappaB signaling pathway.” Biomed Pharmacother. 2018 Jul;103:490-498. doi: 10.1016/j.biopha.2018.04.074. Epub 2018 Apr 24.

[30] Tang J, Li B, Hong S, Liu C, Min J, Hu M, Li Y, Liu Y, Hong L (2017) – « Punicalagin suppresses the proliferation and invasion of cervical cancer cells through inhibition of the beta-catenin pathway.” Mol Med Rep. 2017 Aug;16(2):1439-1444. doi: 10.3892/mmr.2017.6687. Epub 2017 Jun 6

[31] Koyama S, Cobb LJ, Mehta HH, Seeram NP, Heber D, Pantuck AJ, Cohen P (2010) – “Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis.” Growth Horm IGF Res. 2010 Feb;20(1):55-62. doi: 10.1016/j.ghir.2009.09.003. Epub 2009 Oct 22.

[32] Larrosa M, Tomás-Barberán FA, Espín JC (2006) – “The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway.” J Nutr Biochem. 2006 Sep;17(9):611-25. doi: 10.1016/j.jnutbio.2005.09.004. Epub 2005 Oct 11.

[33] Brighenti V, Iseppi R, Pinzi L, Mincuzzi A, Ippolito A, Messi P, Sanzani SM, Rastelli G, Pellati F. (2021) – “Antifungal Activity and DNA Topoisomerase Inhibition of Hydrolysable Tannins from Punica granatum L.” Int J Mol Sci. 2021 Apr 17;22(8):4175. doi: 10.3390/ijms22084175.

[34] Silva TC, de Ávila RI, Zara ALSA, Santos AS, Ataídes F, Freitas VAQ, Costa CR, Valadares MC, Silva MDRR (2020) – « Punicalagin triggers ergosterol biosynthesis disruption and cell cycle arrest in Cryptococcus gattii and Candida albicans : Action mechanisms of punicalagin against yeasts.” Braz J Microbiol. 2020 Dec;51(4):1719-1727. doi: 10.1007/s42770-020-00364-4. Epub 2020 Aug 27.

[35] Sukumar MR, König B (2018) – “Pomegranate extract specifically inhibits Clostridium difficile growth and toxin production without disturbing the beneficial bacteria in vitro.” Infect Drug Resist. 2018 Nov 16;11:2357-2362. doi: 10.2147/IDR.S163484. eCollection 2018.

[36] Mun SH, Kang OH, Kong R, Zhou T, Kim SA, Shin DW, Kwon DY (2018) – “Punicalagin suppresses methicillin resistance of Staphylococcus aureus to oxacillin.” J Pharmacol Sci. 2018 Aug;137(4):317-323. doi: 10.1016/j.jphs.2017.10.008. Epub 2017 Dec 27.

[37] Li G, Feng Y, Xu Y, Wu Q, Han Q, Liang X, Yang B, Wang X, Xia X (2015) – « The anti-infective activity of punicalagin against Salmonella enterica subsp. enterica serovar typhimurium in mice.” Food Funct. 2015 Jul;6(7):2357-64. doi: 10.1039/c5fo00053j.

[38] Li G, Yan C, Xu Y, Feng Y, Wu Q, Lv X, Yang B, Wang X, Xia X (2014) – “Punicalagin inhibits Salmonella virulence factors and has anti-quorum-sensing potential “ Appl Environ Microbiol. 2014 Oct;80(19):6204-11. doi: 10.1128/AEM.01458-14. Epub 2014 Aug 1.

[39] Li G, Xu Y, Wang X, Zhang B, Shi C, Zhang W, Xia X (2014) – « Tannin-rich fraction from pomegranate rind damages membrane of Listeria monocytogenes.” Foodborne Pathog Dis. 2014 Apr;11(4):313-9. doi: 10.1089/fpd.2013.1675. Epub 2014 Jan 21.

[40] Yang Y, Xiu J, Zhang L, Qin C, Liu J (2012) – « Antiviral activity of punicalagin toward human enterovirus 71 in vitro and in vivo.” Phytomedicine. 2012 Dec 15;20(1):67-70. doi: 10.1016/j.phymed.2012.08.012. Epub 2012 Nov 10.

[41] Haidari M, Ali M, Ward Casscells S 3rd, Madjid M (2009) – “Pomegranate (Punica granatum) purified polyphenol extract inhibits influenza virus and has a synergistic effect with oseltamivir.” Phytomedicine. 2009 Dec;16(12):1127-36. doi: 10.1016/j.phymed.2009.06.002. Epub 2009 Jul 7.

[42] Dobroslawa Bialonska, Sashi G Kasimsetty, Kevin K Schrader, Daneel Ferreira (2009) – “The effect of pomegranate (Punica granatum L.) byproducts and ellagitannins on the growth of human gut bacteria” J Agric Food Chem 2009 Sep 23;57(18):8344-9. doi: 10.1021/jf901931b.

[43] D, Ramnani P, Kasimsetty SG, Muntha KR, Gibson GR, Ferreira D (2010) – “The influence of pomegranate by-product and punicalagins on selected groups of human intestinal microbiota.” Int J Food Microbiol. 2010 Jun 15;140(2-3):175-82. doi: 10.1016/j.ijfoodmicro.2010.03.038. Epub 2010 Apr 2.

[44] Cao Y, Ren G, Zhang Y, Qin H, An X, Long Y, Chen J, Yang L (2021) – « A new way for punicalagin to alleviate insulin resistance: regulating gut microbiota and autophagy.” Food Nutr Res. 2021 Jul 1;65. doi: 10.29219/fnr.v65.5689. eCollection 2021.

[45] Korovila I, Jung T, Deubel S, Grune T, Ott C (2020) – “Punicalagin Attenuates Palmitate-Induced Lipid Droplet Content by Simultaneously Improving Autophagy in Hepatocytes.” Mol Nutr Food Res. 2020 Oct;64(20):e2000816. doi: 10.1002/mnfr.202000816. Epub 2020 Sep 28.

[46] Luo J, Long Y, Ren G, Zhang Y, Chen J, Huang R, Yang L (2019) – « Punicalagin Reversed the Hepatic Injury of Tetrachloromethane by Antioxidation and Enhancement of Autophagy.” J Med Food. 2019 Dec;22(12):1271-1279. doi: 10.1089/jmf.2019.4411. Epub 2019 Nov 12.

[47] Zhang Y, Cao Y, Chen J, Qin H, Yang L (2019) – « A New Possible Mechanism by Which Punicalagin Protects against Liver Injury Induced by Type 2 Diabetes Mellitus: Upregulation of Autophagy via the Akt/FoxO3a Signaling Pathway. “ J Agric Food Chem. 2019 Dec 18;67(50):13948-13959. doi: 10.1021/acs.jafc.9b05910. Epub 2019 Dec 9.

[48] Lapaquette P, Bizeau JB, Acar N, Bringer MA (2021) – “Reciprocal interactions between gut microbiota and autophagy.” World J Gastroenterol. 2021 Dec 28;27(48):8283-8301. doi: 10.3748/wjg.v27.i48.8283.

[49] Thein W, Po WW, Choi WS, Sohn UD (2021) – “Autophagy and Digestive Disorders: Advances in Understanding and Therapeutic Approaches.” Biomol Ther (Seoul). 2021 Jul 1;29(4):353-364. doi: 10.4062/biomolther.2021.086.

[50] Liu H, Zhan Q, Miao X, Xia X, Yang G, Peng X, Yan C (2021) – “Punicalagin Prevents Hepatic Steatosis through Improving Lipid Homeostasis and Inflammation in Liver and Adipose Tissue and Modulating Gut Microbiota in Western Diet-Fed Mice.” Mol Nutr Food Res. 2021 Feb;65(4):e2001031. doi: 10.1002/mnfr.202001031. Epub 2021 Jan 12.

[51] Cao K , Wang K , Yang M , Liu X , Lv W , Liu J (2020) – “Punicalagin improves hepatic lipid metabolism via modulation of oxidative stress and mitochondrial biogenesis in hyperlipidemic mice.” Food Funct. 2020 Nov 18;11(11):9624-9633. doi: 10.1039/d0fo01545h.

[52] Atrahimovich D, Samson AO, Khattib A, Vaya J, Khatib S (2018) – “Punicalagin Decreases Serum Glucose Levels and Increases PON1 Activity and HDL Anti-Inflammatory Values in Balb/c Mice Fed a High-Fat Diet.” Oxid Med Cell Longev. 2018 Jul 31;2018:2673076. doi: 10.1155/2018/2673076. eCollection 2018.

[53] Kang B, Kim CY, Hwang J, Jo K, Kim S, Suh HJ, Choi HS (2019) – “Punicalagin, a Pomegranate-Derived Ellagitannin, Suppresses Obesity and Obesity-Induced Inflammatory Responses Via the Nrf2/Keap1 Signaling Pathway.” Mol Nutr Food Res. 2019 Nov;63(22):e1900574. doi: 10.1002/mnfr.201900574. Epub 2019 Sep 3.

[54] Xu L, He S, Yin P, Li D, Mei C, Yu X, Shi Y, Jiang L, Liu F (2016) – “Punicalagin induces Nrf2 translocation and HO-1 expression via PI3K/Akt, protecting rat intestinal epithelial cells from oxidative stress.” Int J Hyperthermia. 2016 Aug;32(5):465-73. doi: 10.3109/02656736.2016.1155762. Epub 2016 Apr 7.

[55] Yan C, Sun W, Wang X, Long J, Liu X, Feng Z, Liu J (2016) – “Punicalagin attenuates palmitate-induced lipotoxicity in HepG2 cells by activating the Keap1-Nrf2 antioxidant defense system.” Mol Nutr Food Res. 2016 May;60(5):1139-49. doi: 10.1002/mnfr.201500490. Epub 2016 Apr 14.

[56] Wahlström A, Sayin SI, Marschall HU, Bäckhed F (2016) – “Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism.” Cell Metab. 2016 Jul 12;24(1):41-50. doi: 10.1016/j.cmet.2016.05.005. Epub 2016 Jun 16.

[57] Hering NA, Luettig J, Jebautzke B, Schulzke JD, Rosenthal R (2021) – “The Punicalagin Metabolites Ellagic Acid and Urolithin A Exert Different Strengthening and Anti-Inflammatory Effects on Tight Junction-Mediated Intestinal Barrier Function In Vitro.” Front Pharmacol. 2021 Mar 10;12:610164. doi: 10.3389/fphar.2021.610164. eCollection 2021.

[58] Marín M, María Giner R, Ríos JL, Recio MC (2013) – “Intestinal anti-inflammatory activity of ellagic acid in the acute and chronic dextrane sulfate sodium models of mice colitis.” J Ethnopharmacol. 2013 Dec 12;150(3):925-34. doi: 10.1016/j.jep.2013.09.030. Epub 2013 Oct 17.

[59] Rosillo MA, Sánchez-Hidalgo M, Cárdeno A, Aparicio-Soto M, Sánchez-Fidalgo S, Villegas I, de la Lastra CA (2012) – “Dietary supplementation of an ellagic acid-enriched pomegranate extract attenuates chronic colonic inflammation in rats.” Pharmacol Res. 2012 Sep;66(3):235-42. doi: 10.1016/j.phrs.2012.05.006. Epub 2012 Jun 4.

[60] Xiao Y, Li K, Bian J, Liu H, Zhai X, El-Omar E, Han L, Gong L, Wang M. (2022) – “Urolithin A Attenuates Diabetes-Associated Cognitive Impairment by Ameliorating Intestinal Barrier Dysfunction via N-glycan Biosynthesis Pathway.” Mol Nutr Food Res. 2022 Feb 20:e2100863. doi: 10.1002/mnfr.202100863.

[61] Ghosh S, Banerjee M, Haribabu B, Jala VR (2022) – “Urolithin A attenuates arsenic-induced gut barrier dysfunction.” Arch Toxicol. 2022 Apr;96(4):987-1007. doi: 10.1007/s00204-022-03232-2. Epub 2022 Feb 5.

[62] Zhang Y, Dong Y, Lu P, Wang X, Li W, Dong H, Fan S, Li D (2021) – “Gut metabolite Urolithin A mitigates ionizing radiation-induced intestinal damage.” J Cell Mol Med. 2021 Nov;25(21):10306-10312. doi: 10.1111/jcmm.16951. Epub 2021 Oct 1.

[63] Singh R, Chandrashekharappa S, Bodduluri SR, Baby BV, Hegde B, Kotla NG, Hiwale AA, Saiyed T, Patel P, Vijay-Kumar M, Langille MGI, Douglas GM, Cheng X, Rouchka EC, Waigel SJ, Dryden GW, Alatassi H, Zhang HG, Haribabu B, Vemula PK, Jala VR. (2019) – “Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway.” Nat Commun. 2019 Jan 9;10(1):89. doi: 10.1038/s41467-018-07859-7.